Cargando…
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
The endocrine effects of 125 mg (low dose) aminoglutethimide (AG) twice daily (b.d.) were compared with those of 125 mg AG + 20 mg hydrocortisone (HC) b.d. in 23 and 45 postmenopausal patients with advanced breast cancer, respectively. The patients in each group were drawn from two separate populati...
Autores principales: | Dowsett, M., Harris, A. L., Stuart-Harris, R., Hill, M., Cantwell, B. M., Smith, I. E., Jeffcoate, S. L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1985
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977250/ https://www.ncbi.nlm.nih.gov/pubmed/2933050 |
Ejemplares similares
-
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1983) -
Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984) -
Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1983) -
Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1985) -
The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.
por: Dowsett, M., et al.
Publicado: (1988)